GLPG
Galapagos N.V.
NASDAQ · Healthcare · Biotechnology · BE
$27.98
+1.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 1.1B | 275.6M | 239.7M | 241.2M |
| Cost of Revenue | 20.8M | 29.7M | 34.9M | 38.9M | 31.4M |
| Gross Profit | 1.0B | 1.1B | 240.8M | 239.7M | 241.2M |
| Operating Expenses | |||||
| R&D Expense | 307.6M | 459.4M | 335.5M | 241.3M | 269.8M |
| SG&A Expense | 91.8M | 112.0M | 96.9M | 94.3M | 103.3M |
| General & Admin Expense | 92.8M | 110.6M | 94.1M | 92.5M | 102.0M |
| Selling & Marketing Expense | (1.0M) | 1.4M | 2.8M | 1.8M | 1.3M |
| Other Expenses | 231.9M | 9.7M | (3.2M) | (7.6M) | (802.0K) |
| Total Operating Expenses | 631.3M | 581.1M | 429.1M | 328.0M | 372.3M |
| Cost and Expenses | 652.1M | 610.9M | 464.0M | 328.0M | 372.3M |
| Operating Income (EBIT) | 391.6M | 501.4M | (188.3M) | (88.3M) | (131.1M) |
| Non-Operating | |||||
| Interest Income | 10.0M | 46.3M | 89.8M | 79.3M | 18.1M |
| Interest Expense | 25.3M | 2.2M | 911.0K | 1.7M | 9.2M |
| Net Interest Income | (14.7M) | 44.1M | 88.9M | 77.6M | 8.9M |
| Other Non-Op Income/Expense | 79.6M | (200.5M) | 185.3M | 93.9M | 60.2M |
| Non-Operating Income (excl Interest) | 193.9M | 198.3M | (186.2M) | (95.7M) | (69.4M) |
| EBT (Pre-Tax Income) | 471.2M | 300.9M | (3.1M) | 5.6M | (70.8M) |
| Income Tax Expense | (16.7M) | (18.6M) | (1.8M) | 9.6M | 572.0K |
| Bottom Line | |||||
| Net Income | 488.8M | 320.9M | 74.1M | 211.7M | (218.0M) |
| Earnings from Cont. Ops | 487.9M | 319.5M | (1.3M) | (4.0M) | (71.4M) |
| Earnings from Discont. Ops | 848.0K | 1.4M | 75.4M | 215.7M | (146.6M) |
| Bottom Line Net Income | 486.9M | 320.9M | 74.1M | 211.7M | (218.0M) |
| Per Share | |||||
| Basic EPS | $7.39 | $4.85 | $1.12 | ($0.06) | ($3.32) |
| Diluted EPS | $7.39 | $4.85 | $1.12 | ($0.06) | ($3.32) |
| Revenue Per Share | $15.84 | $16.81 | $4.17 | $3.64 | $3.67 |
| Shares | |||||
| Basic Shares Outstanding | 65.9M | 66.2M | 66.1M | 65.9M | 65.7M |
| Diluted Shares Outstanding | 65.9M | 65.9M | 66.1M | 65.9M | 65.7M |
| Profitability Metrics | |||||
| EBITDA | 206.1M | 359.0M | 43.3M | 51.0M | 3.9M |
| D&A | 8.4M | 55.9M | 45.5M | 43.6M | 65.6M |
| EBIT | 197.7M | 303.1M | (2.2M) | 7.4M | (61.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026